LeapFrog debuts wearable activity tracker for kids
EMERYVILLE, Calif. — LeapFrog Enterprises, which specializes in educational entertainment for children, on Thursday announced the introduction of LeapBand, the first wearable activity tracker designed for kids that encourages active play and healthy habits.
The LeapBand tracker gets kids up and moving with an array of activities and challenges — 50 in all — that track the child’s physical moves. The more active a child is, the more points they earn. And as the child racks up points for their active play, they unlock additional games, challenges and virtual rewards.
LeapBand’s high-tech features include a built-in accelerometer, a high-res color screen, a rechargeable batter and a water-resistant design. The tracker also comes with eight different customizable pets from LeapFrog’s popular Pet Pals franchise, which can be given a color and a name, adding to the kid-friendly factor.
"We understand that helping a child reach their potential not only includes making sure they are versed on the ABCs and 123s, but they are encouraged through play to establish healthy habits and get the exercise they need every day," said Dr. Jody Sherman LeVos, director of LeapFrog’s Learning Team. "LeapBand is a great way to get kids up and active and help them develop a strong foundation for healthy lifestyles. LeapBand takes inspiration from the growing trend of adult fitness wearables and makes it perfect for kids by bringing the fun and play of physical activities to life with their very own virtual pets."
The LeapBand activity tracker comes with a manufacturer’s suggested retail price of $39.99 and is available in green, pink and blue. Consumers can find it online and at major retail locations beginning August 2014.
L’Oréal survey: Sun care habits lacking despite growing incidence of melanoma
NEW YORK — Despite the growing incidence of melanoma, many women still grade themselves a “C” or lower on their sun care habits, according to a recent survey by L’Oréal Paris and the Melanoma Research Alliance.
According to the findings of the “It’s THAT Worth It Safe Sun Survey,” on melanoma awareness and prevention among women of all skin tones, 52% of American women grade themselves a C or lower on their sun care habits. And, while people of all skin tones are at risk of melanoma, many African American women (36% versus 39% in 2013) and Hispanic women (23% versus 31% in 2013) continue to grade themselves a “D” or “F.” The survey coincides with “Melanoma Monday” on May 5.
The survey reveals that far more women believe they merit an “A” grade when it comes to taking care of their teeth (50%) or eyes (31%) rather than sun care (21%). And while 94% of women have heard of melanoma, and more than half of them believe it’s a serious or potentially deadly condition, only 26% know that they should apply sunscreen all the time, not just in the summer or when they are exposed to direct sunlight.
The “It’s THAT Worth It Safe Sun Survey” was commissioned by L’Oréal Paris, in partnership with the Melanoma Research Alliance, to continue to raise awareness for It’s THAT Worth It, a public health call-to-action that urges women of all skin tones to prevent melanoma by using sunscreen, and to help save lives by supporting melanoma research for a cure. The campaign, which launched on April 8, leverages celebrity spokespeople Eva Longoria, Aimee Mullins, Lea Michele, skin cancer survivor Diane Keaton and L’Oréal Paris executive and melanoma survivor Danielle Macaluso in a series of broadcast and print public service announcements and the "I DO IT" video, as well as the It’s THAT Worth It Thunderclap.
Keaton said, “I was diagnosed with skin cancer at age 21, but that is nothing compared to melanoma, the deadliest form of skin cancer, especially among women under 40. I hope you can join me in a nationwide effort to prevent this killer by visiting ItsTHATworthit.org.”
In addition to the survey, L’Oréal Paris will unveil the "I DO IT" video on ItsTHATworthit.org, featuring the campaign’s celebrity ambassadors. The video shows how they do it by wearing sunscreen every day and asks consumers to wear sunscreen and join the movement.
Those who are interested can join the cause with L’Oréal Paris and MRA by signing up for the Thunderclap on ItsTHATworthit.org from now through May 20. As a thank you, L’Oréal Paris will make a donation to MRA of $1 for each supporter who signs up for the Thunderclap and $1 for each L’Oréal Paris Advanced Suncare product sold in the United States — up to $250,000 in 2014 (the campaign excludes the State of Mississippi). This support is part of a three-year, $750,000 donation by L’Oréal Paris funding MRA research that explores melanoma susceptibility, development and progression. As of today, the Thunderclap has reached 66% of the goal for supporters; the Thunderclap will not be heard unless the goal is reached.
Sales of L’Oréal Paris’ New Advanced Suncare Collection Support MRA L’Oréal Paris’ Sublime Sun collection is now available as Advanced Suncare.
According to the Safe Sun Survey results:
- Women’s dislike of using sunscreen has significantly increased from last year with more women citing texture (15% versus 7% in 2013) and smell (16% versus 10% in 2013) of sunscreen products as something they don’t enjoy.
- This year, significantly more Hispanic women (12% versus 5%) admit they don’t like the way most sunscreens make their skin look.
The survey was conducted online within the United States by Kelton Global on behalf of L’Oréal Paris from April 3 to 9, among 987 women.
FDA approves GSK’s Incruse Ellipta
LONDON — GlaxoSmithKline on Wednesday announced that the Food and Drug Administration approved Incruse Ellipta (umeclidinium), which is used for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, or COPD, including chronic bronchitis and/or emphysema.
Umeclidinium is the company’s first once-daily anticholinergic, a type of bronchodilator also known as a long-acting muscarinic antagonis and is contained in the Ellipta inhaler. The FDA-approved strength is 62.5-mcg.
“We believe Incruse Ellipta, our first monotherapy in the anticholinergic class, will be an important once-daily treatment option for appropriate patients with COPD. GSK has a long-standing commitment to the development of respiratory medicines in order to offer physicians a choice of treatment options for their patients. We are delighted by this approval, and are looking forward to making Incruse Ellipta available for appropriate patients with COPD in the US," said Darrell Baker, SVP and head of GSK Global Respiratory Franchise.
GSK anticipates that launch activities in the United States will begin during fourth quarter 2014.